HomeCompareIMMPF vs FCPT

IMMPF vs FCPT: Dividend Comparison 2026

IMMPF yields 3529.41% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMMPF wins by $2151927237632.54M in total portfolio value
10 years
IMMPF
IMMPF
● Live price
3529.41%
Share price
$0.09
Annual div
$3.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2151927237632.58M
Annual income
$2,038,319,550,631,819,300.00
Full IMMPF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — IMMPF vs FCPT

📍 IMMPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMMPFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMMPF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMMPF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMMPF
Annual income on $10K today (after 15% tax)
$300,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,732,571,618,037,046,300.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, IMMPF beats the other by $1,732,571,618,037,041,400.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMMPF + FCPT for your $10,000?

IMMPF: 50%FCPT: 50%
100% FCPT50/50100% IMMPF
Portfolio after 10yr
$1075963618816.32M
Annual income
$1,019,159,775,315,912,600.00/yr
Blended yield
94.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

IMMPF
No analyst data
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMMPF buys
0
FCPT buys
0
No recent congressional trades found for IMMPF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMMPFFCPT
Forward yield3529.41%6.05%
Annual dividend / share$3.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$2151927237632.58M$49.1K
Annual income after 10y$2,038,319,550,631,819,300.00$5,775.28
Total dividends collected$2144135504039.73M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IMMPF vs FCPT ($10,000, DRIP)

YearIMMPF PortfolioIMMPF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$363,641$352,941.18$11,401$700.92+$352.2KIMMPF
2$12,383,857$11,994,761.18$13,064$864.84+$12.37MIMMPF
3$395,010,981$381,760,253.60$15,051$1,072.48+$395.00MIMMPF
4$11,803,130,868$11,380,469,118.13$17,442$1,337.22+$11803.11MIMMPF
5$330,437,068,596$317,807,718,567.85$20,340$1,677.08+$330437.05MIMMPF
6$8,668,758,125,687$8,315,190,462,289.50$23,880$2,116.57+$8668758.10MIMMPF
7$213,147,085,330,887$203,871,514,136,401.38$28,241$2,689.36+$213147085.30MIMMPF
8$4,912,912,994,478,026$4,684,845,613,173,977.00$33,660$3,442.07+$4912912994.44MIMMPF
9$106,175,408,411,930,130$100,918,591,507,838,660.00$40,456$4,439.95+$106175408411.89MIMMPF
10$2,151,927,237,632,584,700$2,038,319,550,631,819,300.00$49,063$5,775.28+$2151927237632.54MIMMPF

IMMPF vs FCPT: Complete Analysis 2026

IMMPFStock

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Full IMMPF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this IMMPF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMMPF vs SCHDIMMPF vs JEPIIMMPF vs OIMMPF vs KOIMMPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.